The antibody response to Trypanosoma cruzi epimastigote and trypomastigote stages, as well as to laminin, was studied in several groups of chagasic patients. In six patients who were cured of the parasite, the serum antibody titers as revealed by indirect immunofluorescence and hemagglutination tests against epimastigotes (conventional serology) and a complement-mediated lysis test with living trypomastigotes did not differ from those of normal individuals. In seven presumably cured patients, although the complement-mediated lysis test turned negative, conventional serology remained positive. Sera from this group of so-called "dissociated" patients presented significant lower mean antibody titers against epimastigote but not trypomastigote stages than did sera from 14 untreated patients (P < 0.01). Most of the antibodies against trypomastigotes, including the residual levels found in cured patients, were absorbed by mouse laminin. In fact, significantly higher titers of anti-laminin antibodies were observed in sera from untreated chagasic patients (1.131 + 0.458) and cured patients (1.103 ± 0.572) than in sera from eight normal individuals (0.459 ± 0.402) (P < 0.01). The anti-laminin titers were higher in sera of patients of blood group A or O than in those of patients of group B or AB. In Western blotting (immunoblotting) analysis against trypomastigotes, sera from chronic untreated patients recognized many polypeptide bands ranging from 26 to 160 kilodaltons, whereas no protein bands were observed with sera from cured patients. Only faint bands of parasite proteins were observed with sera of dissociated patients. In conjunction, the above data suggest that the anti-trypomastigote antibodies which persist after parasitological cure of patients with Chagas' disease are due mainly to cross-reactive epitopes from mouse lamimn.
Chemotherapy of Chagas' disease with nitroheterocyclic derivatives, although potentially toxic and displaying low efficacy, has been indicated for the treatment of patients with acute and recent chronic asymptomatic cases. In a low percentage of treated patients abrogation of parasite infection can be ascertained by negation of complement-mediated lysis (CoML), which detects protective or lytic antibodies (LA), and by tests such as complement fixation and immunofluorescence which detect conventional serology antibodies (CSA) not involved in protection (9) (10) (11) . In a group of treated patients, LA disappeared but CSA persisted for a long period of time, whereas in all untreated and in most treated and uncured patients, both LA and CSA were present after a long follow-up period.
Since LA are only raised by live Trypanosoma cruzi trypomastigotes (but not by purified or fixed antigens) and are associated with host resistance (9) , their absence in treated patients has been suggested to indicate parasitological cure even though positive CSA may persist (10) . However, there are still some unsettled aspects to be investigated in the humoral immune responses of treated chagasic patients, particularly the persistence of CSA in these seemingly cured patients. Therefore, this investigation was undertaken to compare, in the different groups of treated and untreated chagasic patients, levels and specificities of the antibodies against T. cruzi epimastigote and trypomastigote stages as well as against laminin. Anti-laminin antibodies have been investigated because laminin (a basement membrane glycoprotein that plays a role in the attachment of endothelial and * Corresponding author. epithelial cells to the collagen) has been identified as the main component of the tissue antigens which induce antibodies against heart vascular structures, striated muscle, and interstitium (EVI antibodies) found in chagasic patients (18) and which have been demonstrated to persist in chagasic patients cured by specific treatment (2, 15) . More recently, Towbin et al. (20) reported that anti-laminin antibodies from chagasic sera recognize a carbohydrate epitope present in mouse laminin (but not in human laminin) identified as a terminal galactosyl-a(1-3)galactose (Galal-3Gal). The presence of natural anti-Gal antibodies in normal individuals has also been reported (6, 7 1 :320 in PBS-Tween 20, and 100-ptI samples were added to each well. Ail samples were assayed in triplicate. Plates were then incubated for 1 h at 37°C and washed 10 times with PBS-Tween 20. A 100-pi portion of a 1:1,000 dilution of the peroxidase-conjugated anti-human immunoglobulin (heavy-and light-chain specific) antihuman immunoglobulin G (gamma-chain specific) or antihuman immunoglobulin M (mu-chain specific) (Organon Teknika) was added to each well, the plates were incubated for 1 h at 37°C and washed 10 times with PBS-Tween 20, and then 100 pi of a 1:1 mixture of 2,2-azino-di(3-benzthiazondine sulfonate) (ABTS) and hydrogen peroxide (Kirkegaard and Perry Laboratories, Gaithersburg, Md.) was added to each well. The reaction was stopped by adding 50 pl of 10% sodium dodecyl sulfate solution in each well. Optical density was measured at 405 nm by using an automated ELISA reader (model 2550 EIA Reader; Bio-Rad Laboratories). The results for each serum sample were analyzed by linear regression. The optimal epimastigote and trypomastigote antigen concentrations used to coat the ELISA plates were previously established from a concentration curve and laminin concentration and were used as previously described (18) . Positive-negative control sera were run in all experiments.
Western blot analysis. One thousand micrograms of either epimastigote or trypomastigote antigens was electrophoresed in a gradient sodium dodecyl sulfate-polyacrylamide gel (7.5 to 15%), and the proteins were transferred from the gels to nitrocellulose paper (Bio-Rad) (13, 21) . After transfer, the nitrocellulose paper was blocked by using a solution of 0.15 ptl of PBS (pH 7.2), 0.05% Tween 20, and 0.3% delipidized milk for a period of 90 min. Strips of paper, 0.5-cm wide, were then cut and incubated separately with a 1:50 dilution of human serum for a period of 60 min. Normal human sera were used as controls. After the incubation period, each strip was washed three times in PBS-Tween 20-milk solution, and a 1:500 dilution of peroxidase-labeled goat anti-human immunoglobulin (heavy-and light-chain specific; Organon Teknika) was added to each strip. After 60 min of incubation, the strips were washed as before and the substrate solution of 4-chloro-1-naphthol was added. After color development, the reaction was stopped by immersion of the strips in distilled water. Positive and negative control sera were run in all experiments. Soluble epimastigote antigen preparations were coupled to CNBr-activated Sepharose 4B (Sigma Chemical Co.) and used to absorb anti-epimastigote antibodies from sera of chronically infected chagasic patients. The absorbed sera were used in Western blotting against epimastigote and trypomastigote antigens. The absorbed sera did not react with epimastigote antigens as revealed by Western blotting analysis (data not shown).
CoML test. The CoML test used for detecting LA was done by the method of Krettli et al. (12) . Blood trypomastigotes collected from X-irradiated (550 rads) mice inoculated with the T. cruzi Y strain were collected from the retroorbital plexus, defibrinated with glass beads, and centrifuged at 100 x g for 10 min at room temperature; the trypomastigotes from the supernatant were then concentrated by centrifugation at 1,000 x g for 15 min and washed three times with TC199 with 5% fetal calf serum. Diluted test sera and a blood trypomastigote suspension (7 x 107/ml) (200 ,ul each) were mixed and incubated at 37°C for 30 min. The suspension was then divided into four 50-ulI aliquots maintained on ice, and then 50 ,ul of normal fresh human sera (complement source), or the same sera heat inactivated, was added to the blood trypomastigote suspension in duplicates. The tubes were incubated for 60 min at 37°C, and the percentage of lysis was determined by counting the motile blood trypomastigotes in a hemacytometer. Tests in which the percentage of lysis was higher than 20% were considered positive.
IIF test. The IIF test was performed with T. cruzi epimastigote stages yielded from liquid LIT medium. The parasites were washed twice with PBS-5% fetal calf serum, fixed with 4% Formalin, and washed with PBS without protein. The suspension was adjusted to 7 x 10' parasites per ml, and 20-,ul samples were deposited on the slides, which were kept at -20°C until use. The air-dried preparations were incubated with the diluted sera for 1 h at 37°C, washed, air dried, and incubated with fluorescein-conjugated anti-human immunoglobulin G (Institut Pasteur, Paris, France). After being washed with PBS and dried, the preparations were mounted with alkaline glycerol and examined under UV light in an Statistical analysis. Statistical evaluation of differences between means of experimental groups was determined by the use of analysis of variance and the Scheffé test. Table 1 presents the results of CoML and IIF tests in the group of untreated chagasic patients as well as those of dissociated and cured patients from the treated group. These data clearly show the differences in the occurrences of CSA and LA detected, respectively, by the IIF and CoML tests. Table 2 shows the results of serological tests in which ELISAs were performed in parallel against epimastigote and trypomastigote antigens with sera from untreated, dissociated, and cured patients. A gradual decline in the mean titer of the tests carried out with epimastigote stages was observed in relation to the three groups of patients. A significant difference was detected between the results with sera from untreated patients and those from dissociated and cured patients and normal individuals (P < 0.01). By using an epimastigote/trypomastigote ratio, dissociated and cured patients could be distinguished from the untreated ones (P < 0.01), suggesting that the decline or disappearance of pro- tective antibodies could be inferred from this ratio. This ratio, however, could not discriminate between cured and dissociated patients (P < 0.10).
RESULTS
The analysis of Table 1 and Table 2 shows that both epimastigote and trypomastigote antigens were recognized by antibodies present in the sera of cured (CSA-negative) patients, as demonstrated by the significantly higher mean titers detected in this group than in the normal controls (P < 0.01) in spite of negative CSA results. The participation of anti-laminin antibodies in this phenomenon was studied by using the ELISA with mouse laminin as the antigen (Table  3) . High titers of anti-laminin antibodies were detected in all groups of patients (untreated, dissociated, and cured) when compared with the control group (P < 0.01), although a large variation of antibody titers was observed within the groups. No significant differences existed among the three chagasic groups studied (P < 0.10). When sera of three cured and two dissociated patients were absorbed with laminin, a marked decline in the anti-laminin and anti-trypomastigote (but not epimastigote) ELISA titers was observed (Table 4 ). This is taken as evidence that anti-laminin antibodies in fact participated in the positivity of CSA tests. Table 5 shows the results of serological tests in which
ELISAs were performed in parallel by using mouse and human laminin with sera of chronically infected chagasic patients and normal human sera. The sera of chronic chagasic patients bound to mouse laminin but were three-to sevenfold less reactive with laminin from human placenta. Furthermore, sera from a T. cruzi-infected mouse or rabbit did not react with mouse laminin (Fig. 1) . Recently, Towbin et al. (20) reported that the epitopes of mouse laminin recognized by sera of chagasic patients are carbohydrates presenting a terminal Galal-3Gal. Since antiGal natural antibodies found in normal human sera crossreact with the immunodominant component of the B blood group (6), we compared the levels of antibodies against mouse laminin in sera of chagasic patients of blood groups A and O and groups B and AB (Fig. 2) . The results show that the levels of these antibodies from patients of blood groups lacking B antigens (A and O) are significantly higher than those from patients of groups with such antigens (AB and B) (P < 0.005). Individual and mean A405 generated in ELISA by using sera at a 1:160 dilution from normal individuals (O) and patients with chronic Chagas' disease (*) from distinct blood groups. Assays were done against mouse laminin. Sera from treated and untreated patients were also analyzed by Western blotting against T. cruzi trypomastigote antigens (not shown). Sera from chronically infected untreated patients recognized polypeptides of 160,000, 140,000, 95,000 to 75,000, 51,000, 46,000, 31,000, and 26,000 molecular weight. Most of the proteins of high molecular weight (160,000, 140,000, 95,000 to 75,000) were still recognized by sera that were from chronic-case chagasic patients and that were absorbed with epimastigotes coupled to CNBr-activated Sepharose 4B, suggesting that these proteins are trypomastigote specific. Sera from cured patients recognized no protein bands. Finally, sera from dissociated patients showed only slight binding to those proteins related specifically to trypomastigotes.
DISCUSSION
The findings that LA but not CSA are associated with active T. cruzi infection (9) and that LA disappear in a number of patients submitted to specific treatment are now being used to monitor cures. Prolonged follow-up of several patient groups by using ÇoML, which detects LA, and IIF and complement fixation tests with epimastigote antigens, which detect CSA, has corroborated this idea (10) (11) (12) . According to our experience, 10 (4) . In our group of cured and dissociated chagasic patients, the persistence of anti-laminin antibodies was also detected (Table 3) . Re- cently, Towbin et al. (20) reported that the epitopes of mouse laminin recognized by sera of chagasic patients are carbohydrates presenting a terminal Galal-3Gal group. A similar epitope that cross-reacts with mouse but not human laminin has been detected as a major membrane component of T. cruzi trypomastigotes but not epimastigotes (3, 18 (Fig. 1) (7) , and, in contrast, they are not found in human tissues (14) .
Our results with ELISA ( Fig. 2) , which show that sera from chagasic patients of blood groups A and O, lacking B antigens, display significantly higher levels of antibodies to anti-mouse laminin than those of blood groups AB and B, are consistent with this interpretation and might have practical implications. The possibility exists, for instance, that cured chagasic patients of groups AB and B are immunotolerant to Galal-3 antigens, presenting lower levels of residual antilaminin antibodies. In fact, Teixeira et al. (19) demonstrated that individuals of blood group O display less morbidity to T. cruzi infection than those of blood groups AB and B. In addition, the variation of anti-laminin titers within the groups (Table 3 ) may be explained by the heterogeneity of the patient blood groups.
In conclusion, we suggest that anti-laminin and possibly other cross-reactive antibodies are responsible for the persistence of residual levels of antibodies against T. cruzi antigens detected in the sera of some patients who are considered cured.
